Cargando…

Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer

BACKGROUND: Breast cancer anti-oestrogen resistance 4 (BCAR4) was identified in a search for genes involved in anti-oestrogen resistance in breast cancer. We explored whether BCAR4 is predictive for tamoxifen resistance and prognostic for tumour aggressiveness, and studied its function. METHODS: BCA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Godinho, M F E, Sieuwerts, A M, Look, M P, Meijer, D, Foekens, J A, Dorssers, L C J, van Agthoven, T
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Genetics and Genomics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967058/ https://www.ncbi.nlm.nih.gov/pubmed/20859285 http://dx.doi.org/10.1038/sj.bjc.6605884

Ejemplares similares

BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib
por: Godinho, M F E, et al.
Publicado: (2012)

Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway
por: Dorssers, Lambert CJ, et al.
Publicado: (2005)

Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells
por: van Agthoven, Ton, et al.
Publicado: (2015)

CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer
por: van Agthoven, T, et al.
Publicado: (2009)

Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance
por: Luo, L-Y, et al.
Publicado: (2002)

Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
por: Foekens, J A, et al.
Publicado: (1999)

Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours
por: Reiman, A, et al.
Publicado: (2011)

The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types
por: Forget, M-A, et al.
Publicado: (2007)

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
por: Foekens, J. A., et al.
Publicado: (1994)

Phosphoserine aminotransferase 1 is associated to poor outcome on tamoxifen therapy in recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2017)

The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy
por: Tan, E Y, et al.
Publicado: (2009)

Identification of a Putative Protein Profile Associated with Tamoxifen Therapy Resistance in Breast Cancer
por: Umar, Arzu, et al.
Publicado: (2009)

Multicolour-banding fluorescence in situ hybridisation (mbanding-FISH) to identify recurrent chromosomal alterations in breast tumour cell lines
por: Letessier, A, et al.
Publicado: (2005)

MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours
por: Tanic, M, et al.
Publicado: (2013)

Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease
por: Foekens, J A, et al.
Publicado: (2003)

Association of microRNA-7 and its binding partner CDR1-AS with the prognosis and prediction of 1(st)-line tamoxifen therapy in breast cancer
por: Uhr, K., et al.
Publicado: (2018)

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer
por: Birkeland, E, et al.
Publicado: (2012)

High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer
por: Jansen, M. P. H. M., et al.
Publicado: (2011)

Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer
por: Lai, J, et al.
Publicado: (2003)

Somatic glypican 3 (GPC3) mutations in Wilms' tumour
por: White, G R M, et al.
Publicado: (2002)

BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface
por: Lee, A J, et al.
Publicado: (2014)

Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters
por: Fritz, G, et al.
Publicado: (2002)

MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression
por: Presneau, N, et al.
Publicado: (2013)

Effect of different cytokines on mammaglobin and maspin gene expression in normal leukocytes: possible relevance to the assays for the detection of micrometastatic breast cancer
por: Ballestrero, A, et al.
Publicado: (2005)

Methylator phenotype of malignant germ cell tumours in children identifies strong candidates for chemotherapy resistance
por: Jeyapalan, J N, et al.
Publicado: (2011)

The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer
por: Law, Emily K., et al.
Publicado: (2016)

Circulating leukocyte telomere length and risk of overall and aggressive prostate cancer
por: Julin, B, et al.
Publicado: (2015)

Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours
por: von Bueren, A O, et al.
Publicado: (2012)

Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-α-based isolated hepatic perfusion
por: van Etten, B, et al.
Publicado: (2003)

Gene expression profiling of human ovarian tumours
por: Biade, S, et al.
Publicado: (2006)

Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer
por: De Faveri, L E, et al.
Publicado: (2013)

Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study
por: Hsieh, Szu-Min, et al.
Publicado: (2009)

Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays
por: Bièche, I, et al.
Publicado: (2002)

Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation
por: Marsh, H P, et al.
Publicado: (2003)

Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment
por: Campbell, Aideen M, et al.
Publicado: (2018)

Promoter hypermethylation of MGMT, CDH1, RAR-β and SYK tumour suppressor genes in granulosa cell tumours (GCTs) of ovarian origin
por: Dhillon, V S, et al.
Publicado: (2004)

Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer
por: Cooke, S L, et al.
Publicado: (2011)

CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours
por: Sodha, N, et al.
Publicado: (2002)

Identification of novel neuroendocrine-specific tumour genes
por: Hofsli, E, et al.
Publicado: (2008)

Common genetic variants in the 9p21 region and their associations with multiple tumours
por: Gu, F, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1rlc6kvcfmeulgll1hncedrbsk